Special Issue

Advances in Liquid Biopsy for the Diagnosis of Breast Cancer

Message from the Guest Editor

Liquid biopsy refers to the process of obtaining tumorderived material, such as tumor DNA, RNA, or extracellular vesicles, from body fluids such as blood, urine, and saliva. The relatively non-invasive nature of the material obtained using methods such as blood or urine collection makes it an attractive method of investigation compared to traditional tumor biopsy. It also has the advantage of overcoming the problem of tumor heterogeneity by sampling the entire genomic environment of the tumor present in the patient's body, and it provides the possibility of repeating the test over time, allowing for longitudinal monitoring of the tumor and anti-inflammatory drugs. It may also have potential for the early detection of cancer, predicting prognosis, and predicting response to treatment. In recent years, the development of highly sensitive assays capable of detecting tumor-derived material in body fluids, often in minutes, has made liquid biopsy a viable alternative to conventional tumor biopsy.

Guest Editor

Dr. Chihwan David Cha

Department of Surgery, Hanyang University College of Medicine, Seoul, Republic of Korea

Deadline for manuscript submissions

31 August 2025



Diagnostics

an Open Access Journal by MDPI

Impact Factor 3.3 CiteScore 5.9 Indexed in PubMed



mdpi.com/si/192215

Diagnostics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diagnostics@mdpi.com

mdpi.com/journal/diagnostics





Diagnostics

an Open Access Journal by MDPI

Impact Factor 3.3 CiteScore 5.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Andreas Kjaer

Department of Clinical Physiology, Nuclear Medicine & PET National University Hospital, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

